- Home
- CELC vs CBZ Comparison
CELC vs CBZ Comparison
Compare CELC & CBZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CELC | CBZ |
|---|---|---|
| Founded | 2011 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.7B |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | CELC | CBZ |
|---|---|---|
| Price | $104.77 | $53.53 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $100.13 | N/A |
| AVG Volume (30 Days) | ★ 863.3K | 500.5K |
| Earning Date | 11-12-2025 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.66 |
| Revenue | N/A | ★ $2,675,607,000.00 |
| Revenue This Year | N/A | $55.67 |
| Revenue Next Year | N/A | $6.13 |
| P/E Ratio | ★ N/A | $32.36 |
| Revenue Growth | N/A | ★ 59.19 |
| 52 Week Low | $7.58 | $47.89 |
| 52 Week High | $112.64 | $90.13 |
Technical Indicators
Market Signals| Indicator | CELC | CBZ |
|---|---|---|
| Relative Strength Index (RSI) | 63.88 | 56.51 |
| Support Level | $98.50 | $49.79 |
| Resistance Level | $103.09 | $54.42 |
| Average True Range (ATR) | 3.54 | 1.53 |
| MACD | -0.65 | 0.06 |
| Stochastic Oscillator | 78.85 | 78.73 |
Price Performance
Historical ComparisonAbout CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About CBZ CBIZ Inc.
CBIZ Inc through its subsidiaries provides professional services advisors to middle-market businesses and organizations nationwide. Its business units have been aggregated into three practice groups: Financial Services, Benefits and Insurance Services, and National Practices. The company provides its services to various industries such as Banking & Financial Services, Commercial Real Estate, Construction, Health Care Manufacturing & Distribution NFP & Education, Private Client Services, Professional Services, Public Sector, and Technology & Life Sciences. It derives the majority of its revenues from the Financial Services segment and geographically from the United States.